ராபர்ட் ஹேஸ்லெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ராபர்ட் ஹேஸ்லெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ராபர்ட் ஹேஸ்லெட் Today - Breaking & Trending Today

MannKind Corporation (MNKD) Q1 2021 Earnings Call Transcript


Operator
Good afternoon, and welcome to MannKind Corporation first-quarter 2021 earnings call. As a reminder this call is being recorded on May 12th, 2021, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until May 26, 2021. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from these stated expectations.
For further information on the company s risk factors please see their 10-Q report filed with the Securities and Exchange Commission this morning, the earnings release and the slides prepared for this presentation. Joining us today from Mannkind are Chief Executive Officer Michael Castagna, and Chief Financial Officer Steven Binder. I would now like to turn the conference over to Mr. Castagna. ....

United States , Oren Livnat , Steven Binder , Michael Castagna , Stephen Lichtman , Robert Hazlett , Steve Binder , Thomas Smith , Connor Daly , Exchange Commission , Mannkind Corporation , Stephen Lichtman Oppenheimer Co , Receptor Life Sciences , Oren Livnat Hc Wainwright Co , Amann Group , Chief Executive Officer Michael Castagna , Chief Financial Officer Steven , United Therapeutics , Receptor Life , Levin Type , ஒன்றுபட்டது மாநிலங்களில் , ஒரேன் லிவ்னாட் , ஸ்டீவன் பைண்டர் , மைக்கேல் காஸ்டஞ , ராபர்ட் ஹேஸ்லெட் , ஸ்டீவ் பைண்டர் ,

Why Seelos Therapeutics Stock Is Skyrocketing Today


Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Seelos Therapeutics (NASDAQ:SEEL) were skyrocketing 35.2% higher as of 11:01 a.m. EST on Friday. The huge gain came after BTIG initiated coverage on the stock with a buy recommendation and a one-year price target nearly 4.7 times higher than Seelos closing price on Thursday.
So what
Investors shouldn t buy a biotech stock (or any other stock, for that matter) just because an analyst likes it. However, it s always a good idea to gain an understanding of the reasons behind the bullish view. ....

Robert Hazlett , Seelos Therapeutics , ராபர்ட் ஹேஸ்லெட் , சீலோஸ் சிகிச்சை ,